drugset / Trial / NCT04526704
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is designed to evaluate the discontinuation/re-treatment of pexidartinib therapy in previously treated participants with tenosynovial giant cell tumor (TGCT).
Timeline
- Start
- 2020-10-20
- Primary completion
- 2023-07-07
- Completion
- 2023-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pexidartinib | Small molecule | 200 mg | Oral |